Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report report published on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $85.00 target price on the stock.

Several other analysts have also issued reports on PVLA. Raymond James Financial set a $54.00 price target on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. HC Wainwright raised their target price on Palvella Therapeutics from $38.00 to $75.00 and gave the company a “buy” rating in a report on Friday, August 15th. Chardan Capital lifted their price target on Palvella Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Lifesci Capital started coverage on Palvella Therapeutics in a research report on Monday, August 4th. They set an “outperform” rating and a $90.00 price objective for the company. Finally, Canaccord Genuity Group raised their price objective on Palvella Therapeutics from $52.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $60.91.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $56.71 on Tuesday. The stock has a market capitalization of $627.21 million, a P/E ratio of -4.69 and a beta of -0.03. The stock’s fifty day moving average is $40.70 and its 200 day moving average is $29.68. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $58.22.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). Equities research analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics during the 2nd quarter worth $37,000. Spire Wealth Management acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at about $70,000. JPMorgan Chase & Co. increased its stake in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics during the second quarter worth about $85,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Palvella Therapeutics during the second quarter worth about $104,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.